Quick Answer
Stoke Therapeutics, Inc. reported Net Income of -$6.88 million for fiscal year 2025.
Stoke Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$6.88M | +92.3% |
| 2024 | -$88.98M | +15.0% |
| 2023 | -$104.70M | -3.6% |
| 2022 | -$101.07M | -17.8% |
| 2021 | -$85.81M | -64.2% |
| 2020 | -$52.24M | -61.6% |
| 2019 | -$32.33M | -158.2% |
| 2018 | -$12.52M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$38.35M | -45.1% | -63.3% |
| June 30, 2025 | -$23.48M | +8.6% | -120.8% |
| March 31, 2025 | $112.88M | +528.0% | +527.1% |
| September 30, 2024 | -$26.43M | -7.7% | -2.9% |
| June 30, 2024 | -$25.70M | +16.2% | +2.6% |
| March 31, 2024 | -$26.37M | -17.0% | -7.5% |
| September 30, 2023 | -$24.54M | +6.0% | +19.9% |
| June 30, 2023 | -$30.65M | -24.3% | -36.0% |
- Stoke Therapeutics, Inc. showed an increase of +92.3% in Net Income compared to the prior fiscal year.
- Over the 2018–2025 period, Stoke Therapeutics, Inc.’s net income has grown by 45.0% (from -$12.52 million to -$6.88 million).
- The most recent figure is from Stoke Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: